AmerisourceBergen’s Update on the Distribution of Donated Remdesivir from Gilead Sciences, released May 5, 2020, provides the following information:
On May 1, 2020, the FDA granted an Emergency Use Authorization (EUA) for Gilead’s remdesivir for the treatment of COVID-19. Gilead has been working closely with the U.S. government on preparations to donate and distribute remdesivir across the country to treat critical COVID-19 patients, and will work with AmerisourceBergen as the sole distributor for the donated remdesivir.
Given the severity of illness of patients appropriate for remdesivir treatment and the limited availability of drug supply, hospitals with intensive care units and other hospitals that the U.S. government deems most in need will receive priority in the distribution of donated remdesivir. The U.S. government will coordinate the distribution of remdesivir to hospitals in regions most heavily impacted by COVID-19. Neither Gilead nor AmerisourceBergen are deciding which hospitals will receive remdesivir.
If you are a hospital identified by the U.S. government as a recipient for donated remdesivir, you will be proactively contacted by an AmerisourceBergen representative. Retail and specialty pharmacies are not eligible to receive donated remdesivir.
We will update this message as additional information becomes available.
Enter our Sweepstakes now for your chance to win the following prizes:
Just answer the following quick question for your chance to win:
Entries are limited to one entry per person in any active sweepstakes.
Thank you for your entry.